The Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024.Â
Adam Glanzman | Bloomberg | Getty Images
Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.
Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year. The majority of those sales will come from Moderna’s Covid shot and newly launched vaccine for respiratory syncytial virus, according to a release.
The guidance is down from a prior forecast range of $2.5 billion to $3.5 billion issued in September. At the time, the company said it expects to break even on an operating cash basis in 2028 — pushed back from 2026 — with $6 billion in revenue.
Shares of Moderna plunged 18% in premarket trading Monday. Other vaccine stocks also…
